Acute myeloid leukaemia (AML) is a heterogeneous, most common type ofacute leukaemia that involves mutation in haematopoietic and progenitorsstem cells (HPSCs) leading to uncontrolled division, self-renewal anddifferentiation. Though it was untreatable about a half century ago, AML isnow considered to be treatable in up to 40% of adults and those who are ator under 60 years of age. For the post-induction treatment, the mutationtesting and cytogenetics are still an important prognostic tool. The AMLtreatment remains unchanged for almost three decades, although the fieldis advanced with the discovery of new drugs and deep understanding of thedisease biology. Still, many people are relapsing and are dying eventuallyfrom the disease. This review discusses the broader aspects of AML,reflecting some of the most important and productive areas of research onthe subject and was conducted using thoroughly searching databases,including Health Research and Development Information network Plus(HERDIN Plus), google scholar and PubMed to critically analysesthe recentadvances, available treatments and future prospectives of AML.
Keywords: AML; Pathogenesis; Treatment; Relapse